BrainStorm Cell Therapeutics Inc. (BCLI) Posts Earnings Results, Beats Expectations By $0.02 EPS
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its earnings results on Tuesday. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02.
Shares of BrainStorm Cell Therapeutics (NASDAQ:BCLI) opened at 2.165 on Wednesday. The company’s market capitalization is $40.39 million. The company has a 50 day moving average of $2.30 and a 200-day moving average of $2.39. BrainStorm Cell Therapeutics has a 12-month low of $1.90 and a 12-month high of $3.87.
Separately, Maxim Group set a $5.00 target price on shares of BrainStorm Cell Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 11th.
An institutional investor recently raised its position in BrainStorm Cell Therapeutics stock. Vanguard Group Inc. raised its position in shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 1.3% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 491,867 shares of the biotechnology company’s stock after buying an additional 6,200 shares during the period. Vanguard Group Inc. owned approximately 2.64% of BrainStorm Cell Therapeutics worth $1,186,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.75% of the company’s stock.
BrainStorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Stock Ratings for BrainStorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainStorm Cell Therapeutics Inc. and related stocks with our FREE daily email newsletter.